Skip to search formSkip to main contentSkip to account menu

TOK-001

Known as: VN/124, VN/124-1 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

galeterone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
The fluorescent two-hybrid assay for live-cell profiling of androgen receptor modulators
Review
2016
Review
2016
Editorial Comment to Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
Androgen receptor (AR) has been a main target in prostate cancer therapy. The exhausting battle against AR mutation or splicing… 
Review
2015
Review
2015
[New therapies in metastatic castration resistant prostate cancer].
2015
2015
Comparisons of Prostate Cancer Inhibitors Abiraterone and TOK-001 Binding with CYP17A1 through Molecular Dynamics
Review
2014
Review
2014
The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor
Prostate cancer treatment has evolvedthrough the varying eras of therapy fromone of predominantly hormonal agentswithout much… 
2014
2014
Re: J. Alfred Witjes. A case of abiraterone acetate withdrawal. Eur urol 2013;64:517-8.
2013
2013
Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer
Androgen deprivation therapy (ADT) with medical or surgical castration is the mainstay of therapy in men with metastatic prostate… 
2012
2012
Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC).
4665 Background: Galeterone is an oral steroid analog that suppresses prostate cancer growth by inhibiting CYP17, blocking… 
Review
2012
Review
2012
Antihormonelle Therapie des Prostatakarzinoms der 3. Generation
ZusammenfassungDer Nachweis einer intrazellulären Androgensynthese durch Prostatakarzinomzellen hat dazu geführt, neue… 
2012
2012
Abstract LB-248: Investigation of tumor cell activity of Abiraterone using in vitro model systems of androgen (A)-responsive prostate cancer
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Objective Abiraterone acetate (AA) has recently… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)